Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B244 topical spray in pediatric atopic dermatitis
NCT03775434Phase 1Completed
- Sponsor
- AOBiome
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B244 in atopic dermatitis (AD), sponsored by AOBiome. Primary endpoints: Treatment-emergent Adverse Events at Day 28, Clinically Significant Changes in Physical Exam at Day 28 and 3 more. Started Dec 2018; status: completed.
02
Drugs
B244
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03775434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775434.